Trial Profile
Multicentre Pilot Study of Dihydropyrimidine Dehydrogenase (DPD) Deficiency for Predicting Capecitabine Toxicity in Breast Cancer Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- Acronyms DPD BREAST; DPD SEIN
- 18 Aug 2009 New trial record